Rheumatology Advance Access originally published online on October 23, 2007
Rheumatology 2008 47(1):102-103; doi:10.1093/rheumatology/kem242
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© The Author 2007. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org
LETTERS TO THE EDITOR |
Study of two polymorphisms of the MHC2TA gene with systemic lupus erythematosus
Consejo Superior de Investigaciones Científicas, CSIC, 1Servicio de Medicina Interna, Hospital Virgen de las Nieves, 2Servicio de Medicina Interna, Hospital Clínico San Cecilio, Granada, 3Servicio de Medicina Interna, Hospital Carlos-Haya, Malaga, 4Servicio de Reumatología, Hospital Virgen de la Victoria, Málaga and 5Servicio de Inmunología, Hospital Virgen de las Nieves, Granada, Spain
Correspondence to: E. Sánchez, Instituto de Parasitología y Biomedicina López-Neyra, CSIC, Parque Tecnológico de Ciencias de la Salud., Avenida del Conocimiento s/n 18100-Armilla (Granada), Spain. E-mail: elena@ipb.csic.es
| The first 10% of the full text of this article appears below. |
SIR, Systemic lupus erythematosus (SLE) is a prototypic autoimmune disease with a complex pathogenesis which involves multiple genetic and environmental factors. Although the pathogenesis of SLE is unknown, a strong genetic component is well established. Among the genetic factors believed to influence susceptibility to SLE, the major histocompatibility complex (MHC) alleles show the most significant association. The mechanism by which these alleles increase the risk of SLE is unknown. However, it seems that regulatory factors of expression of MHC class II molecules could